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Hepatocellular carcinoma (HCC) is the third leading cause of cancer death
worldwide. HCC treatment is hindered by the frequent emergence of
chemoresistance to the multikinase inhibitor sorafenib, which has been
related to the presence of cancer stem cells (CSCs) that self-renew and
often escape therapy. The key metabolic sensor AMP-activated kinase
(AMPK) has recently been recognized as a tumour growth regulator. In
this study, we aimed to elucidate the role of AMPK in the development of
a stem cell phenotype in HCC cells. To this end, we enriched the CSC pop-
ulation in HCC cell lines that showed increased expression of drug resis-
tance (ALDH1A1, ABCB1A) and stem cell (CD133, Nanog, Oct4, alpha
fetoprotein) markers and demonstrated their stemness phenotype. These
cells were refractory to sorafenib-induced cell death. We report that sorafe-
nib-resistant cells had lower levels of total and phosphorylated AMPK as
well as its downstream substrate, ACC, compared with the parental cells.
Interestingly, AMPK knockdown with siRNA or inhibition with dorso-
morphin increased the expression of stem cell markers in parental cells and
blocked sorafenib-induced cell death. Conversely, the upregulation of
AMPK, either by transfection or by pharmacological activation with A-
769662, decreased the expression of ALDH1A1, ABCB1A, CD133, Nanog,
Oct4, and alpha fetoprotein, and restored sensitivity to sorafenib. Analysis
of the underlying mechanism points to hypoxia-inducible factor HIF-1a as
a regulator of stemness. In vivo studies in a xenograft mouse model demon-
strated that stem-like cells have greater tumourigenic capacity. AMPK acti-
vation reduced xenograft tumour growth and decreased the expression of
stem cell markers. Taken together, these results indicate that AMPK may
serve as a novel target to overcome chemoresistance in HCC.
Abbreviations
ACC, acetyl-CoA carboxylase; AFP, alpha fetoprotein; ALDH1A1, aldehyde dehydrogenase isoform 1A1; AMP, adenosine monophosphate;
AMPK, AMP-activated kinase; CAP, capsaicin; CSC, cancer stem cell; GFAP, glial fibrillary acidic protein; HCC, hepatocellular carcinoma;
HIF-1a, hypoxia-inducible factor 1a; Oct4, octamer-binding transcription factor 4; PGC1a, proliferator-activated receptor-c coactivator 1-a;
PPARc, proliferator-activated receptor-c; SF, sorafenib.
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1. Introduction
Cancer continues to be the second leading cause of
death in Western countries. More than 2 million new
cases of cancer and 610 000 cancer deaths are pre-
dicted to occur only in the United States during 2018
(Siegel et al., 2018). Hepatocellular carcinoma (HCC)
is the most common liver malignancy in adults and the
third leading cause of cancer mortality worldwide
(Beal et al., 2017). The prognosis for patients with
advanced HCC remains extremely poor due to the
high resistance to cytotoxic therapy. For the past dec-
ade, the multikinase inhibitor sorafenib has been the
only approved standard treatment for patients with
advanced HCC (Kudo, 2017), albeit it only extends life
expectancy by 2–3 months (Cheng et al., 2009; Llovet
et al., 2008; Tovoli et al., 2018). This can be attributed
to the acquisition of resistance, predominantly due to
the upregulation of certain survival pathways that may
cover up the death signals induced by sorafenib (Zhu
et al., 2017). Several clinical trials have investigated
other multitargeted kinase inhibitors, but none have
shown any benefits over single-agent sorafenib. In
August 2018, the Food and Drug Administration
approved lenvatinib for first-line treatment of patients
with unresectable hepatocellular carcinoma based on
overall survival results obtained in clinical trials
(Kudo, 2018; Spallanzani et al., 2018). Nevertheless, it
is still too early to know whether this drug produces
long-term secondary effects or resistance. Hence, the
elucidation of the underlying mechanisms of evasive
resistance is required to overcome unwanted tumour
recurrence and, consequently, to improve the beneficial
effects of chemotherapy.
Drug resistance to conventional chemotherapeutic
agents has been closely related to many intrinsic or
acquired properties associated with the presence of
cancer stem cells (CSCs), which possess higher prolifer-
ative output and the ability to self-renew. CSCs over-
express drug resistance genes, such as drug efflux
transporters or detoxifying enzymes, which confer pro-
tection from the adverse effects of chemotherapeutic
insult (Begicevic and Falasca, 2017). Therefore, to pre-
vent drug resistance and tumour recurrence, it is
imperative to gain a better understanding of the mech-
anisms involved in the resistance of stem cells to
chemotherapy, which could lead to the discovery of
new targets that can be exploited with a therapeutic
purpose.
Previous research has shown that the isolation of
hepatocellular CSC (HCC-CSC) can be performed
using cell surface stemness-associated markers, such as
the transmembrane glycoprotein CD133, alpha feto-
protein (AFP), or aldehyde dehydrogenase isoform
1A1 (ALDH1A1), which have been used for further
HCC-CSC classification into different prognostic sub-
types (Dai et al., 2018; Ma et al., 2008a). In particular,
HCC-CSCs expressing CD133 were associated with a
poor prognosis because they bear great tumourigenic
potential, possess greater colony-forming efficiency
and display chemoresistance to the classical anticancer
drugs doxorubicin and fluorouracil (Ma et al., 2008b).
Although the underlying molecular mechanisms of
chemoresistance in these cells are not completely clear,
the data indicate sustained activation of the PI3K/Akt
cascade (Ma et al., 2008b). In line with this, signalling
pathways involved in the acquired resistance to sorafe-
nib include activation of the PI3K/Akt and JAK/
STAT axes, the induction of HIF-1a-mediated adapta-
tion to hypoxia or the upregulation of FGF signalling
pathways (Zhu et al., 2017). Similarly, recent findings
showed that the sensitivity to sorafenib after develop-
ing resistance can be restored with PI3K/Akt inhibi-
tors (Wu et al., 2016; Yi et al., 2017).
Our recent research on HCC resistance demon-
strated that activation of the enzyme AMP-activated
kinase (AMPK) inhibits the PI3K/Akt pathway and
sensitizes HCC cells to sorafenib (Bort et al., 2017). In
addition, we demonstrated that the activation of
AMPK by cannabinoids induces autophagy and sup-
presses HCC cell proliferation (Vara et al., 2011).
Moreover, emerging evidence suggests that metformin,
an AMPK activator used as an antidiabetic drug,
resensitizes resistant cancer cells to chemotherapy by
targeting several signalling pathways, including AMPK
(Ling et al., 2014; You et al., 2016). In this regard,
recent evidence demonstrates that metformin inhibits
CSC proliferation (Finley, 2017; Saini and Yang,
2018) and reduces the expression of stemness markers
(Paiva-Oliveira et al., 2018). Therefore, AMPK
emerges as a new target that could be involved in drug
resistance and the development of CSCs.
In this study, we analysed the role of AMPK in the
development of stem-like cells and in the sorafenib
resistance of HCC cells. We show that the downregu-
lation of AMPK plays a key role in mediating an
increase in the expression of stemness markers and
that the pharmacological activation of AMPK or
AMPK overexpression overcomes this stem cell-like
phenotype. Furthermore, sorafenib resistance was
associated with stemness and was abrogated by
AMPK transfection or activation. Our results expand
the role of AMPK in cancer and highlight novel treat-
ment options for resistant cancer.
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2. Materials and methods
2.1. Reagents and antibodies
Sorafenib was purchased from Sigma-Aldrich (St.
Louis, MO, USA). The compound A-769662 and cap-
saicin were purchased from Tocris Bioscience (Bristol,
UK). The primary antibodies anti-CD133, anti-
ALDH1A1, anti-pAkt-ser473, p-mTOR, pAMPKa1-
thr172, pACC-ser79, anti-cyclin D1, anti-PGC1a, and
anti-PPARc and the antibodies against the corre-
sponding total forms were obtained from Cell Signal-
ing Technology (Danvers, MA, USA). The primary
antibody anti-b-catenin was purchased from Santa
Cruz Biotechnology (Dallas, Texas, USA). The pri-
mary antibody anti-Hif-1a was purchased from Novus
(St. Louis, MO, USA). Anti-alpha fetoprotein and per-
oxidase-labelled secondary anti-mouse IgG were pur-
chased from Sigma-Aldrich, and anti-rabbit IgG was
purchased from Calbiochem (San Diego, USA).
2.2. Cell lines and cell culture
The human hepatocellular carcinoma HepG2 cell line
was purchased from the American Type Culture Col-
lection (ATCC HB-8065, Rockville, MD, USA). The
human hepatoma cell line Huh7 was kindly provided
by L. Bosca (Instituto de Investigaciones Biomedicas
Alberto Sols, Madrid). Cell lines were incubated at
37 °C in a humidified atmosphere with 5% CO2 and
cultured in DMEM/10% FBS supplemented with 1%
nonessential amino acids, 100 IUmL1 penicillin G
sodium, 100 lgmL1 streptomycin sulphate, and
0.25 lgmL1 amphotericin B (Invitrogen, Paisley,
UK).
To generate cancer stem-like cells, HepG2 and
Huh7 cells were cultured continuously for 12 months
with a step-wise increase in the sorafenib concentration
(starting at 0.75 lM and increasing the concentration
by 0.15 lM at each passage up to a final concentration
of 8 lM). Surviving cells were selected and designated
as HepG2SF1 and Huh7SF1 cells. HepG2 and Huh7
parental cells were cultured in parallel without sorafe-
nib and served as controls.
2.3. Cell proliferation assay
Cell proliferation was analysed using the MTT assay.
Briefly, 5 9 103 cells/well was seeded into 12-well plates
and allowed to attach and grow for 24 h. After
treatment with sorafenib for 24 h, 200 lL of MTT (3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide) dye solution (Sigma-Aldrich) was added to
each well and incubated at 37 °C for 4 h. Subsequently,
the cells were lysed with 2-propanol to dissolve the for-
mazan crystals. Then, the optical density of each well
was measured using a microplate reader (iMARK,
Bio-Rad Laboratories, Inc., Hercules, CA, USA) at a
wavelength of 595 nm, and the nonspecific absorbance
measured at 650 nm was subtracted. Each experiment
was performed in triplicate. Cell viability was calculated
as the percentage compared to the control cells, which
were arbitrarily assigned 100% viability. The half-maxi-
mal inhibitory concentration (IC50) values, defined as
the concentration that inhibited 50% cell growth rela-
tive to control cells, were calculated using GRAPHPAD 6.0
(La Jolla, CA, USA) software.
Cell viability was also determined by counting viable
and dead cells by Trypan blue staining. Trypan blue-
positive and blue-negative cells were counted using a
Countess automated cell counter (Invitrogen, Carls-
bad, CA, USA). The results are expressed in relation
to the total number of cells counted.
2.4 Colony forming assay
Cells were seeded in flat-bottom six-well plates at dif-
ferent densities. Two weeks later, the medium was
removed. Colonies were fixed in methanol, stained
with 0.05% (w/v) crystal violet solution for 5 min,
washed with PBS and counted.
2.5. Differentiation assay
For the in vitro differentiation of stem-like cells into
neurons, stem-like cells (1 9 105 cells/well) were
seeded into 6-well plates and incubated in phenol red-
free neurobasal medium (Invitrogen) supplemented
with 2% B-27 serum-free supplement (Invitrogen), 2%
CSS, and 2 mM L-glutamine (Invitrogen) for 15 days.
For glial redifferentiation, stem-like cells were incu-
bated in phenol red-free DMEM (Sigma-Aldrich) with
1% N-2 supplement (Invitrogen), 2% CSS and 2 mM
L-glutamine (Invitrogen).
2.6. Western blot analysis
After treatment or transfection for 48 h, cells were
harvested, and proteins were extracted using lysis buf-
fer (50 mM Tris, pH 7.4, 0.8 M NaCl, 5 mM MgCl2,
0.1% Triton X-100) containing protease inhibitor and
phosphatase inhibitor cocktail (Roche, Diagnostics;
Mannheim, Germany), incubated on ice for 15 min
and cleared by microcentrifugation. Protein concentra-
tions were measured using the Bio-RadTM protein assay
kit (Richmond, CA, USA). The cell protein extracts
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(20 lg) were boiled for 5 min in loading buffer and
then separated on 8–15% SDS/PAGE gels depending
on the protein to be analysed. The separated protein
bands were transferred onto a PVDF membrane and
incubated with the primary antibodies diluted 1 : 1000
overnight at 4 °C. Horseradish peroxidase-conjugated
goat anti-mouse and goat anti-rabbit IgG secondary
antibodies were then added at a dilution ratio of
1 : 2000, and the membranes were incubated at room
temperature for 2 h. The immune complex was visual-
ized with an ECL system (Cell Signaling Technology).
2.7. Flow cytometry
A total of 5 9 105 HCC cells were seeded into 6-well
plates and treated according to the experiment. The
cells were then harvested in 0.35% trypsin, collected
and centrifuged at 1500 g for 5 min at 4 °C. Subse-
quently, the cells were washed in 1 mL ice-cold PBS
and then centrifuged at 1500 g for 5 min at 4 °C. The
cells were then incubated with an anti-human CD133
antibody Alexa Fluor 488 conjugate (Cell Signaling
Technology) at room temperature for 1 h. The cells
were then washed twice with wash buffer to remove
excess antibody and analysed on a FACSCalibur flow
cytometry system (BD Biosciences, San Jose, CA,
USA) using CYFLOGIC software V1.2.1 (Perttu Terho,
Mika Korkeamaki, CyFlo Ltd., Turku, Finland). A
total of 104 events were collected for each sample.
2.8. Confocal microscopy
The cells were fixed in 4% paraformaldehyde in PBS and
incubated with 0.1% Triton X-100 for permeabilization.
Immunolabelling with an anti-bIII tubulin polyclonal anti-
body (Covance, Princeton, NJ, USA) or an anti-GFAP
(glial fibrillary acidic protein) monoclonal antibody
(Thermo Scientific, Waltham, MA, USA) was performed
by incubation at room temperature for 1 h. Secondary
labelling was performed with Alexa Fluor 488-conjugated
secondary antibodies (Invitrogen). Coverslips were then
mounted with DAPI-containing Mowiol mounting med-
ium (Sigma-Aldrich). Imaging was performed with a Leica
TCS SP5 laser scanning confocal microscope with LAS-AF
IMAGING software using a 40X oil objective. The quantifi-
cation of images was performed with IMAGEJ v1.8.0 soft-
ware (NIH Image, Bethesda, MD, USA).
2.9 RNA extraction and reverse transcription
quantitative polymerase chain reaction
Total cellular RNA was extracted from sensitive and
resistant cells using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s pro-
tocol. Total RNA (2–4 lg) underwent cDNA synthesis
using SuperScriptTM RT (Roche, Basel, Switzerland)
according to the manufacturer’s protocol. qPCR was
performed in a 10 lL volume using SYBR-Green PCR
Master Mix (Takara Bio, Inc., Kusatsu, Japan) on a
7500 Real-Time PCR System (Applied Biosystems Inc.,
Foster City, CA, USA) according to the manufacturer’s
protocols. PCR amplification was carried out using the
following primer sequences: Nanog-F 50-TTTGTGG
GCCTGAAGAAAACT-30, Nanog-R 50-AGGGCTG
TCCTGAATAAGCAG-30; Oct4-F 50-GACAGGGGG
AGGGGAGGAGCTAGG-30, Oct4-R 50-CTTCCCT
CCAACCAGTTGCCCCAAAC-30; and ABCB1A-F 50-
TTGCTGCTTACATTCAGGTTTCA-30, ABCB1A-R
50-AGCCTATCTCCTGTCGCATTA-30.
2.10. siRNA transfections
Cells were transfected in 1 mL OPTIMEM containing
4 lg Lipofectamine iMax (Invitrogen) with 100 nM
AMPK-specific small interfering RNA (siRNA) duplexes
(Ambion-Life Technologies, Carlsbad, CA, USA) or
scrambled RNA (control) according to the manufac-
turer’s protocols (Invitrogen). At 48 h after transfection,
the medium was removed and replaced with DMEM. At
the indicated time points after transfection, cells were used
for MTT cell viability assays or western blot analysis.
2.11. Transient transfections
Plasmids encoding the full-length human AMPK-a1,
AMPK-b1 and AMPK-c1 were kindly provided by G.
Hardie (University of Dundee, UK). Sensitive and resis-
tant HepG2 and Huh7 cells were cotransfected with 5 lg
recombinant a1 (pcDNA5-FRT a1-Flag), b1 (pCMV
b1-untagged) and c1 WT (pcDNA5-Flpln-T10 c1 WT-
Flag) plasmids using 5 lL Lipofectamine 3000 (Thermo
Fisher) in antibiotic-free medium and seeded into 12-well
plates. After 48 h of transfection, the transfection med-
ium was replaced with another medium without serum,
and the cells were maintained for 24 h and then assayed
for cell viability. Protein expression was assayed by west-
ern blotting using anti-FLAG antibodies (anti-Flag M2
antibody, Sigma-Aldrich). For tetracycline-inducible
plasmids, Flag-tagged pcDNA5-Flpln-T10 protein
expression was induced by the addition of 1 lgmL1
tetracycline in the transfection medium.
2.12. Animal studies
All animal experiments followed the ARRIVE guideli-
nes and were carried out in accordance with the U.K.
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Animals (Scientific Procedures) Act, 1986, and associ-
ated guidelines, EU Directive 2010/63/EU for animal
experiments. The procedure was approved by the
Alcala University Ethical Commission and by the Eth-
ical Commission of the Comunidad de Madrid (proce-
dure PROEX 241/15). All animal studies were
conducted in accordance with the Spanish institutional
regulation (RD 53/2013) for the housing, care and use
of experimental animals and met the European
Community directives regulating animal research. Rec-
ommendations made by the United Kingdom Coordi-
nating Committee on Cancer Research (UKCCCR)
were followed carefully. To assess the welfare of ani-
mals, a panel of 10 indicators were recorded each day.
When adverse effects, pain or distress was observed in
the animals (score of 15 of 40), a humane endpoint
was applied.
Athymic nude-Foxn1 (nu/nu) four-week-old mice
were purchased from Envigo RMS (Barcelona, Spain)
and housed in a laminar air flow cabinet under patho-
gen-free conditions on a 12-h light/dark schedule at
21–23 °C and 40-60% humidity with access to food
pellets and tap water ad libitum. Four animals were
housed per cage. G Power analysis was used to calcu-
late the sample size (Charan and Kantharia, 2013)
according to our previous data and experience and
considering a two-tail effect and a significance level of
5%. Hepatocarcinoma tumours were induced in
athymic mice by subcutaneous injection of 5 9 106
HepG2 or HepG2SF1 cells. When tumours reached a
volume of 70 mm3, mice were then randomly divided
into experimental groups of 6 animals each, which
received i.p. injections of 30 mgkg1 sorafenib (SF),
5 mgkg1 capsaicin or vehicle (DMSO) daily. Tum-
our size was measured daily and calculated using the
formula V(mm3) = 1/2(length 9 width2). At the end
of the study, the mice were sacrificed by placing them
in a CO2 gas-filled chamber, and the excised tumours
were recovered and weighed. For the tumourigenic
assay, hepatocarcinoma tumours were induced by sub-
cutaneous injection of 2.5 9 106, 5 9 106, 10 9 106
or 15 9 106 HepG2 or HepG2SF1 cells on both sides
of the mice. Tumour development was examined daily,
and tumour volumes were calculated as indicated
above.
2.13. Statistical analysis
Statistical significance was estimated with GRAPHPAD
6.0 (La Jolla, CA, USA) software using 1-way or 2-
way ANOVA and Tukey’s multiple comparison test or
the unpaired Student’s t-test when indicated. Data are
presented as the mean SD.
2.14. Data availability
The datasets generated and/or analysed during the cur-
rent study are available at https://doi.org/10.17632/yp
w4d3j9wb.1.
3. Results
3.1. Sorafenib resistance in HCC cells induces a
stem-like phenotype
Drug resistance has been frequently associated
with the emergence of cancer stem cells (Phi et al.,
2018). To study the resistance mechanisms in HCC
cells, we induced sorafenib-resistant cells by long-term
incubation of HepG2 and Huh7 HCC cell lines with
step-wise increasing concentrations of sorafenib (0.75–
8 lM). After 12 months of exposure, the surviving cells
that had routinely grown in the presence of 8 lM sor-
afenib were selected and designated as HepG2SF1 and
Huh7SF1 cells.
To investigate whether long-term sorafenib treat-
ment induced CSC differentiation in HCC cultures, we
analysed the expression of the cell membrane protein
CD133, which was recently identified as a stem cell
marker in HCC (Castelli et al., 2017). According to
previous data (Suetsugu et al., 2006), parental HepG2
cells do not express CD133 (Fig. 1A). Likewise, in
Huh7 cells, CD133 is barely expressed (Fig. 1A). Inter-
estingly, in HepG2SF1 cells treated with sorafenib
long term, there was a slight increase in CD133 expres-
sion, whereas in Huh7SF1 cells, a notable increase in
CD133 expression was observed (Fig. 1A). Flow
cytometry determination of CD133 confirmed its
increase in HepG2SF1 and Huh7SF1 cells (Figs 1A
and S1). As CD133 was poorly detected in HepG2
cells, we examined the embryonic protein alpha feto-
protein (ΑFP), which has also been proposed as a stem
cell marker and is clearly detected in HepG2 cells (but
not in Huh7 cells). As shown in Fig. 1A, ΑFP expres-
sion increased in HepG2SF1 cells treated with sorafe-
nib long term, indicating the acquisition of a stem-like
phenotype. To further investigate this hypothesis, we
examined the expression of other stem cell-associated
genes, such as aldehyde dehydrogenase isoform 1A1
(ALDH1A1), a cytosolic enzyme that metabolizes
reactive aldehydes and reactive oxygen species. Due to
its role in metabolism, this detoxifying enzyme can
confer cellular protection against cytotoxic drugs such
as sorafenib. ALDH1A1 expression was increased in
HepG2SF1 and Huh7SF1 cells (Fig. 1A). To examine
the time course of the appearance of these stem mark-
ers, we analysed their expression 6 months after
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sorafenib treatment, and we observed that although A
and CD133 in HepG2SF1 cells and CD133 in
Huh7SF1 cells could be appreciated at 6 months, their
expression was much lower than that at 12 months
(Fig. S1). The enzyme ALDH1A1 was increased only
after 12 months of sorafenib treatment (Fig. S1).
Therefore, we continued the study with cells treated
for 12 months with sorafenib.
We next analysed the expression of ABCB1A or p-
glycoprotein, a member of the multidrug resistant
transporters that actively extrudes a variety of
hydrophobic amphipathic drugs from the cell. This
transporter was only analysed in Huh7 cells because
we were not able to detect ABCB1A in HepG2 cells,
which is probably due to the low expression of this
gene in this cell line. Finally, we examined the tran-
scription factors Nanog and octamer-binding tran-
scription factor 4 (Oct4), which are usually expressed
in embryonic stem cells, where they are involved in
pluripotency regulation, proliferation and renewal.
These transcription factors have also been used to
detect cancer stem cell subpopulations (Iv Santaliz-
Ruiz et al., 2014; van Schaijik et al., 2018; Zheng
et al., 2013). The increased expression of all the genes
analysed in sorafenib-resistant cells (Fig. 1A) indicated
that long-term treatment of HCC cells with sorafenib
induced the expression of proteins involved in drug
resistance and pluripotency, characteristic of cancer
stem cells.
Then, we investigated whether long-term sorafenib
treatment led to other features of cancer stem cells.
Cancer stem cells are capable of forming large colonies
through clonal expansion from a single cell, and clono-
genic activity has been considered an important indica-
tor of undifferentiation (Rajendran and Jain, 2018). In
agreement with this notion, HepG2SF1 and Huh7SF1
cells had a higher capacity of forming colonies than
their parental cells (Fig. 1B). Notably, HepG2SF1 and
Huh7SF1 cells formed colonies even when treated with
sorafenib, whereas their parental cells exhibited
decreased numbers of colonies in the presence of this
drug (Fig. 1B). In addition, HepG2SF1 and Huh7SF1
cells showed a higher proliferation rate than HepG2
and Huh7 cells (Fig. 1C). One of the critical properties
of CSCs is their potential to differentiate into unlim-
ited heterogeneous populations of cancer cells (Desai
et al., 2018). To investigate the differentiation poten-
tial of the long-term sorafenib-treated cells, HepG2,
Huh7, HepG2SF1 and Huh7SF1 cells were incubated
in neuronal differentiation or glial differentiation
media for 15 days. Afterwards, differentiation into
neurons was assessed by determining the expression of
the specific neuronal marker bIII tubulin and differen-
tiation into astrocytes by the expression of glial fibril-
lary acidic protein (GFAP). As shown in Fig. 1D, the
incubation of cells with neuronal differentiation media
induced a notorious increase in the expression of bIII
tubulin in HepG2SF1 and Huh7SF1 cells compared
with their parental cells (Fig. 1D). Likewise, the
expression of GFAP increased in HepG2SF1 and
Huh7SF1 cells when incubated in glial differentiation
media (Fig. 1D). We then examined the tumourigenic
potential of the stem-like cells. According to the Euro-
pean normative on the reduction of animals in
research (3 Rs principle), in vivo experiments were car-
ried out only in the HepG2 cell line. To this end,
HepG2 or HepG2SF1 cells were transplanted to gener-
ate xenograft-derived tumours in mice. The frequencies
of tumour formation were measured after the inocula-
tion of nude mice with either 2.5, 5 or 10 million cells.
As shown in Fig. 1E, tumours derived from
HepG2SF1 cells appeared earlier than those derived
from HepG2 cells, confirming that the stem-like cells
had an enhanced capacity to form xenograft-derived
tumours compared to their parental cells. Likewise,
tumours derived from stem-like cells grew faster than
tumours derived from parental cells (Fig. 1E). Taken
together, these results indicate that HepG2SF1 and
Fig. 1. Long-term treatment of HCC cells with sorafenib induces a stem-like phenotype. (A) HepG2 and Huh7 cells were incubated with
increasing concentrations of sorafenib for 12 months. The levels of stem cell markers were determined by western blot, qPCR and flow
cytometry in parental HepG2 and Huh7 cells as well as in HepG2SF1 and Huh7SF1 cells treated long term with sorafenib. The qPCR data
show the relative mRNA expression of actin, which was used as a housekeeping gene. Data represent the mean  SD of seven
independent experiments. (B) Colony-forming capability (represented as the number of colonies formed/plated cells) of cells in the presence
of vehicle (C) or 8 lM sorafenib (SF). (C) Cell proliferation determined by the MTT assay and cell counting of parental HepG2 and Huh7 and
HepG2SF1 and Huh7SF1 cells treated long term with sorafenib. (D) Differentiation capability of HepG2SF1 and Huh7SF1 cells. Cells were
grown in neuron differentiation media for 21 days, after which the expression of bIII tubulin was determined by immunofluorescence or
western blot. Alternatively, cells were grown in glial differentiation media, and the expression of glial acidic fibrillary protein (GFAP) was
determined by immunofluorescence or western blot. Scale bar of confocal images indicates 25 lm. Data are the mean  SD of three
independent experiments. (E) Tumourigenic potential of HepG2SF1 and Huh7SF1 cells. Nude mice were inoculated with 2.5, 5 or 10 million
HepG2 or HepG2SF1 cells, and tumour size was examined daily. Figure represents the frequency of tumour development (upper left panel)
and the growth curves of the tumours over 15 days (mean  SEM, n = 6). *P ≤ 0.01 compared by Student’s t-test.
6 Molecular Oncology (2019) ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
AMPK impacts hepatocellular cancer stem cells A. Bort et al.
7Molecular Oncology (2019) ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
A. Bort et al. AMPK impacts hepatocellular cancer stem cells
Huh7SF1 cells exhibit phenotypic characteristics of
cancer stem cells.
To investigate whether these stem-like cells were
resistant to sorafenib, cells were treated in the absence
of serum with 0, 1, 2, 3, 5 and 7 lM sorafenib for
24 h. The results in Fig. 2A show that HepG2SF1 and
Huh7SF1 cells could tolerate higher concentrations of
sorafenib in the absence of serum compared to paren-
tal cells, with an IC50 fivefold and threefold higher
than that of HepG2 and Huh7 cells, respectively
(Fig. 2B).
Dysregulated signalling of the PI3K/Akt/mTOR
pathway has been associated with resistance to several
different chemotherapeutic agents, including sorafenib
(Zhu et al., 2017). To address the status of this path-
way, we examined the total and phosphorylation levels
of Akt and mTOR in sensitive and sorafenib-resistant
HCC cells. As shown in Fig. 2B, HepG2SF1 and
Huh7SF1 stem-like cells had higher Akt and mTOR
phosphorylation levels compared to sensitive cells,
which is in good agreement with previous reports
demonstrating the activation of this signalling pathway
in chemotherapy-resistant cells (Dong et al., 2017;
Lindblad et al., 2016).
3.2. AMPK inhibition induces the acquisition of a
stem-like phenotype
We recently showed that AMPK activation increases
HCC cell sensitivity to sorafenib (Bort et al., 2017).
Consequently, we wondered whether AMPK inhibition
was involved in sorafenib-acquired resistance and in
the stem-like cell phenotype of HepG2SF1 and
Huh7SF1 cells. To this end, we first determined the
expression levels of AMPK and its phosphorylation at
the activation site Thr172, as well as the phosphoryla-
tion and levels of its downstream target, acetyl-CoA
carboxylase (ACC), in HepG2SF1 and Huh7SF1 cells.
Decreased phosphorylation and expression of both
AMPK and ACC were clearly observed in sorafenib-
resistant cells compared with their parental cells
(Fig. 3A). Therefore, we examined the effect of
Fig. 2. Chemoresistance of HepG2SF1 and Huh7SF1 cells. (A) Cells were treated with sorafenib at the indicated concentrations for 24 h.
Cell viability was determined by the MTT assay and is expressed as the percentage of the control (DMSO treatment). The table shows the
IC50 values of sorafenib in the four cell lines. Experiments were run in triplicate and carried out three times on separate occasions. (B) The
levels of phosphorylated Akt and mTOR proteins and their total forms were determined by western blot. b-Tubulin (bTub) is shown as a
loading control. A representative image of four different experiments is shown. Densitometric values (mean  SD, n = 4) relative to
controls are shown on the right. *P < 0.005 significant difference between stem-like and parental cells and #P < 0.005 between treated and
nontreated cells by two-way ANOVA and Tukey’s multiple comparisons test.
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Fig. 3. The AMPK inhibition induces stemness in HCC cells. (A) The levels of phosphorylated and total forms of AMPK and ACC in parental
(HepG2 and Huh7) and stem-like HepG2SF1 and Huh7SF1 cells were determined by western blot. b-Tubulin (bTub) is shown as a loading
control. A representative image of four different experiments is shown. Densitometric values (mean  SD, n = 4) relative to controls are
shown on the right. (B) Effect of the AMPK inhibitor dorsomorphin (Dorso) or AMPK knockdown with an siRNA on stem cell marker
expression in parental (HepG2 and Huh7) and stem-like (HepG2SF1 and Huh7SF1) cells as determined by western blot. b-Actin is shown as
a loading control. A representative image of three different experiments is shown. Densitometric values (mean  SD, n = 3) relative to
controls are shown below. (C) The levels of CD133 were determined by flow cytometry in AMPK-knockdown cells.
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AMPK downregulation on the expression of stem cell
markers in HepG2SF1 and Huh7SF1 cells. To this
end, cells were either treated with the AMPK inhibitor
dorsomorphin or transfected with an siRNA targeting
AMPK. As shown in Fig. 3B, AMPK inhibition or
knockdown increased the expression of ΑFP, CD133
and ALDH1A1 in sensitive HepG2 cells and of
CD133 and ALDH1A1 in Huh7 cells. The increase in
CD133 in AMPK-depleted cells was further confirmed
by flow cytometry (Figs 3C and S2). These results sug-
gest a negative role for AMPK in the stemness of
HCC cells.
To address the relevance of AMPK downregulation
in the resistance to sorafenib, we treated sensitive cells
with the AMPK inhibitor dorsomorphin and examined
cell viability. The inhibition of AMPK reduced
sorafenib-induced cell death in sensitive HepG2 and
Huh7 cells (Fig. 4A) but had no effect on stem-like sor-
afenib-resistant cells (Fig. S3). Likewise, AMPK knock-
down with an siRNA completely abolished the
antiproliferative effect of sorafenib in sensitive parental
cells, with no effect on stem-like cells (Figs 4B and S3).
These findings suggest that AMPK activity is necessary
for sorafenib-induced cell death and that AMPK down-
regulation makes cells refractory to sorafenib.
3.3. AMPK upregulation decreases the expression
of stem cell markers in HepG2SF1 and Huh7SF1
cells
To further explore the functions of AMPK as a drug
resistance suppressor, we investigated whether AMPK
Fig. 4. The AMPK inhibition induces sorafenib resistance in HCC cells. (A) Effect of dorsomorphin on the viability of HepG2 and Huh7 cells
treated with sorafenib. Cells were treated with or without 5 lM dorsomorphin and sorafenib at the indicated concentrations for 24 h. Cell
viability was determined by the MTT assay and is expressed as the percentage of the control (DMSO treatment). (B) Effect of AMPK
knockdown on the viability of HepG2 and Huh7 cells treated with sorafenib. Cells were transfected with either siRNA-control or an AMPK-
selective siRNA for 24 h and then treated with sorafenib at the indicated concentrations for 24 h. Cell viability was determined by the MTT
assay and is expressed as the percentage of the control (DMSO treatment). Experiments were run in triplicate and carried out three times
on separate occasions (data are the mean  SD). *P < 0.005 significant difference between resistant and control cells and #P < 0.005
between treated and nontreated cells by two-way ANOVA and Tukey’s multiple comparisons test.
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upregulation could modify the expression of drug
resistance and stem cell markers in sorafenib-refractory
cells. For this purpose, we first induced AMPK expres-
sion by transient transfection with plasmids containing
the AMPK subunits a1, b1 and c1 (Fig. S4). As shown
in Fig. 5A, AMPK transfection notably decreased the
expression of CD133, ALDH1A1 and alpha fetopro-
tein in sorafenib-resistant cells, as determined by west-
ern blot. The determination of CD133 by flow
cytometry confirmed the decrease in this stem cell mar-
ker in HepG2SF1 cells transfected with AMPK
(Figs 5A and S2). Likewise, the levels of the drug
efflux transporter ABCB1A and the embryonic genes
OCT4 and NANOG decreased in AMPK-transfected
cells (Fig. 5A).
We then treated resistant cells with the well-known
AMPK activator A-769662 and capsaicin, which, as
we previously showed, activates AMPK in HepG2 cells
(Bort et al., 2017). As shown in Fig. 5B, A-769662
and capsaicin activated AMPK in both sensitive and
resistant cells. Treatment of HCC cells with A-769662
markedly decreased the expression of ΑFP, CD133
and ALDH1A1 in HepG2SF1 cells as well as the levels
of CD133 and ALDH1A1 in Huh7SF1 cells. The
effect of capsaicin on CD133 levels was similar,
although not as strong. Similarly, A-769662 and cap-
saicin decreased the expression of Nanog, OCT4 and
ABCB1A in the stem-like cells (Fig. 5B).
3.4. AMPK overexpression or activation restores
the sensitivity to sorafenib in stem-like cells
We next examined whether AMPK overexpression
could resensitize stem-like cells to sorafenib. Interest-
ingly, the overexpression of AMPK in HepG2SF1 and
Huh7SF1 cells resulted in sorafenib-induced cell death
at levels comparable with those of sensitive cells
(Fig. 6A). The overexpression of AMPK in sensitive
cells did not modify the effect of sorafenib (Fig. S4).
In agreement with these results, the treatment of stem-
like cells with compound A-769662 or capsaicin resen-
sitized cells to sorafenib (Fig. 6B), whereas it had little
effect on sensitive cells (Fig. S4).
3.5. Potential mechanisms involved in the AMPK
effect
To elucidate the potential mechanisms underlying the
AMPK effect on stem-like cells, we analysed some of
the signalling pathways associated with development
and differentiation in HCC cells transfected with
AMPK. Previous studies have reported that the Wnt/
b-catenin signalling pathway is associated with the
control of stem cell differentiation (Valkenburg et al.,
2011). The activation of this pathway causes the
accumulation of b-catenin in the cytosol, which is
translocated to the nucleus, where it binds to LEF/
TCF transcription factors and regulates the expres-
sion of target genes, including genes involved in dif-
ferentiation and the cell cycle. To investigate whether
the Wnt/b-catenin pathway was activated in HCC
stem-like cells, we determined, by western blot, the
levels of b-catenin and cyclin D1, a downstream tar-
get of b-catenin. The results in Fig. 7 show that
b-catenin and cyclin D1 levels were decreased in
HepG2SF1 and Huh7SF1 cells compared to their
parental cells, while they were increased in AMPK-
transfected cells. It has been demonstrated that
b-catenin, through repression of the transcription fac-
tor TCF7L2, upregulates the expression of peroxisome
proliferator-activated receptor gamma coactivator-1
alpha (PGC-1a), which has been shown to be involved
in hepatocyte differentiation (Jiao et al., 2017; Wanet
et al., 2017). In contrast, AMPK can directly phospho-
rylate and activate PGC-1a and regulate its expression
(Colombo and Moncada, 2009). Therefore, we anal-
ysed PGC1a levels in HCC cells and observed that this
coactivator was downregulated in stem-like HepG2SF1
and Huh7SF1 cells (Fig. 7), in concordance with
AMPK levels in those cells. In line with this, the levels
of peroxisome proliferator-activated receptor gamma
(PPARc) were decreased in stem-like cells (Fig. 7).
Interestingly, the overexpression of AMPK by transient
transfection increased the levels of PGC1a and PPARc
(Fig. 7).
Recent findings have indicated that the hypoxia-
inducible factors HIF-1a and HIF-2a play critical
roles in the gain of more malignant phenotypes by
cancer stem cells (Mimeault and Batra, 2013). More
specifically, it has been observed that hypoxia and
enhanced HIF-1a and HIF-2a expression and activity,
which frequently occur during tumour progression,
may result in the upregulation of different stemness
gene products that increase tumourigenicity (Heddle-
ston et al., 2009; Ma et al., 2011; Mimeault and Batra,
2013). Importantly, it has been described that the
downregulation of AMPK under normoxia induces a
sustained increase in HIF-1a and cooperates with c-
myc to increase tumourigenesis (Faubert et al., 2013).
Thus, we determined the levels of HIF-1a in
HepG2SF1 and Huh7SF1 cells transfected with
AMPK. As shown in Fig. 7, the stem-like cells
HepG2SF1 and Huh7SF1 had increased levels of HIF-
1a, suggesting that the depletion of AMPK could
reverse the inhibition of this transcription factor,
which might be involved in the upregulation of stem
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cell markers observed in these cells (Fig. S5). Notably,
the levels of HIF-1a decreased in AMPK-transfected
cells, in agreement with the observed decrease in stem
cell markers under these conditions. All these results
indicate that AMPK, by downregulating PGC-1a and
PPARc and by upregulating HIF-1a, could induce
HCC stem cell reprogramming and restore sorafenib
sensitivity.
3.6. AMPK activation reduces the tumour growth
of stem-like cells in vivo
To further assess the effects of sorafenib resistance on
tumour growth in vivo, HepG2 or HepG2SF1 cells
were inoculated in mice. Once the tumour size reached
70 mm3, the animals were randomly divided into
groups and treated with vehicle, 30 mgkg1 sorafenib,
Fig. 6. The AMPK upregulation restores sorafenib sensitivity in HCC cells. (A) Effect of the transient expression of AMPKa1b1c1 on cell
viability in HepG2SF1 and Huh7SF1 cells treated with increasing concentrations of sorafenib. Cells were treated with sorafenib at the
indicated concentrations for 24 h. Cell viability was determined by the MTT assay and is expressed as the percentage of the control (DMSO
treatment). Experiments were run in triplicate and carried out three times on separate occasions. (B) Effect of the AMPK activator A-769662
and capsaicin on cell viability in HepG2SF1 and Huh7SF1 cells treated with increasing concentrations of sorafenib. Cells were treated as
described above. Experiments were run in quadruplicate and carried out three times on separate occasions (data are the mean  SD).
#P < 0.005 significant difference between AMPK-transfected and nontransfected cells (panel A) or between control and treated cells (panel
B).
Fig. 5. The AMPK upregulation decreases the expression of stem cell markers in HepG2SF1 and Huh7SF1 cells. (A) The levels of stem cell
markers in parental HepG2 and Huh7 cells and stem-like HepG2SF1 and Huh7SF1 cells transfected with AMPK a1b1c1 were determined by
western blot and qPCR. b-Actin is shown as a loading control in western blots. A representative image of three different experiments is
shown. Densitometric values (mean  SD, n = 3) relative to controls are shown on the right. The qPCR data show the relative mRNA
expression of actin, which was used as a housekeeping gene. (B) The levels of pAMPK, pACC and stem cell markers were determined by
western blot and qPCR in cells treated with the AMPK activator A-769662 and capsaicin. A representative image of three different
experiments is shown. Densitometric values (mean  SD, n = 3) relative to controls are shown below. The qPCR data show the relative
mRNA expression of actin, which was used as a housekeeping gene. *P < 0.005 significant difference between resistant and control cells
by two-way ANOVA and Tukey’s multiple comparisons test, #P < 0.005 significant difference between AMPK-transfected and
nontransfected cells (panel A) or between control and treated cells (panel B).
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5 mgkg1 capsaicin or both compounds simultane-
ously for 12 days. We treated the mice with capsaicin
since compound A769662 has shown poor bioavail-
ability in vivo (Cool et al., 2006), and we have previous
data on the in vivo AMPK activation by capsaicin
(Bort et al., 2017). Tumour volumes were calculated
daily. After sacrifice, the size and weight of the tumour
were measured. The stem-like HepG2SF1 cells had
greater tumourigenicity than their parental HepG2
cells, since the tumours reached 70 mm3 twice as fast
(data not shown). As shown in Fig. 8A, HepG2SF1
tumours grew clearly faster, especially in the last
5 days, when tumours grew exponentially. Moreover,
sorafenib-treated HepG2SF1 tumours grew at a similar
rate as vehicle-treated HepG2SF1 cells, further con-
firming the drug resistance developed by these cells.
However, as expected, sorafenib reduced tumour
growth in HepG2-sensitive tumours (Fig. 8A). Nota-
bly, capsaicin was very efficient in reducing the tumour
growth of stem-like cells, which grew at a similar rate
as that of parental cells (Fig. 8A). Likewise, stem-like
tumour weight at the end of the treatment was not
significantly different between vehicle- and sorafenib-
treated mice, whereas it was significantly reduced by
capsaicin (Fig. 8B). By contrast, the weights of sensi-
tive tumours treated with sorafenib were significantly
reduced compared with the vehicle-treated animals.
Molecular analyses of sorafenib-treated xenografts
corroborated our findings in cell cultures. Immunoblot
analysis of tumour lysates showed that tumours devel-
oped from stem-like HepG2SF1 cells had increased
expression of AFP, CD133 and ALDH1A1 as well as
upregulation of the Akt/mTOR axis and lower expres-
sion of pAMPK, AMPK, pACC and ACC (Fig. 8C).
Sorafenib treatment of HepG2 tumours slightly
increased the expression of ΑFP, while sorafenib treat-
ment of stem-like tumours reduced the expression of
CD133 but did not induce a significant modification of
AFP or ALDH1A1. Interestingly, treatment of mice
with capsaicin and especially with the combination of
capsaicin and sorafenib activated AMPK and markedly
reduced the expression of AFP, CD133 and ALDH1A1
(Fig. 8C), suggesting AMPK activation as a strategy to
reduce stem-like properties and resistance in vivo.
Fig. 7. The AMPK transfection counteracts b-catenin, cyclin D1, PGC1a and PPARc downregulation and HIF-1a upregulation in stem-like
cells. HepG2 and Huh7 cells and stem-like HepG2SF1 and Huh7SF1 cells were transfected with AMPK a1b1c1, and the levels of b-catenin,
cyclin D1, PGC-1a, PPARc and HIF-1a were determined by western blot. b-Actin is shown as a loading control. A representative image of
two different experiments is shown.
Fig. 8. In vivo activity of sorafenib and capsaicin in stem-like cells. (A) The growth curves of HepG2 and HepG2SF1 cells as tumour
xenografts in nude mice treated with vehicle (diamonds), 30 mgkg1day1 sorafenib (squares), 5 mgkg1day1 capsaicin (circles) or both
(triangles). Data are shown as the mean  SEM; n = 6. (B) Tumour weights at the end of treatment (mean  SEM). (C) The levels of
proteins in the tumours dissected at the end of the treatment were determined by western blot. b-Actin is shown as a loading control. A
representative image of one of the six tumours of each treatment is shown. Densitometric values (mean  SD, n = 6) relative to controls
are shown on the left. *P < 0.005 significant difference between resistant tumours and sensitive tumours; #P < 0.005 between treated and
nontreated tumours and ¥P < 0.005 between capsaicin- and sorafenib-treated tumours by two-way ANOVA and Tukey’s multiple
comparisons test.
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4. Discussion
Sorafenib resistance remains a major problem for the
effective treatment of hepatocellular carcinoma
because sorafenib is the only standard clinical treat-
ment against the advanced form of this disease (Chen
et al., 2015a). The therapeutic benefit of this com-
pound is limited, and invariably, tumour progression
reappears (Le Grazie et al., 2017). Therefore, it is nec-
essary to identify signalling pathways that promote
drug resistance and to explore potential strategies to
overcome resistance to find more effective therapies. In
this study, we analysed the role of AMP-activated
kinase in the development of the cancer stem cell phe-
notype in two HCC cell lines. HepG2 and Huh7 cells
grown in the presence of sorafenib for 12 months
showed higher expression of drug resistance
(ALDH1A1, ABCB1A) and stem-related (CD133,
OCT4, Nanog, alpha fetoprotein) genes and had
higher clonogenic capacity, a higher proliferation rate
and differentiation ability and increased tumourigenic
potential, suggesting that sorafenib resistance induced
or selected stem-like cells. Although the biological
function of CD133 is not well understood, it currently
serves as a useful marker for liver cancer stem cells.
Studies by Ma et al. (2008a) found that CD133-posi-
tive HCC cells possessed greater colony-forming effi-
ciency, a higher proliferative output and a greater
ability to form tumours in vivo. The tumourigenic
potential of those HCC cells correlated with the
expression of both CD133 and ALDH (Ma et al.,
2008a). Moreover, the overexpression of CD133 in 127
HCC specimens was associated with a poor prognosis
(Dai et al., 2018). Recent results have shown that
CD133 may interact with the regulatory subunit of
PI3K, stabilizing AKT signalling and conferring CSC-
like properties to hepatocellular carcinoma (Jang et al.,
2017a,b). Our results are in good agreement with these
observations, as CD133-positive cells presented higher
proliferative and tumourigenic potential. In addition,
we show that long-term treatment of HCC cells with
increasing doses of sorafenib induces the expression of
pluripotency genes and converts them into highly
aggressive and resistant cells. In agreement with our
results, previous data showed that Nanog+ Huh7 cells
exhibited increased chemoresistance, self-renewal,
sphere formation ability and in vivo tumour incidence
compared to Nanog Huh 7 cells (Shan et al., 2012)
when considering the Oct4 and Nanog transcription
factors as gatekeepers of pluripotency (Lee et al.,
2017; Seymour et al., 2015). In our study, the elevated
expression of stem cell genes in HepG2SF1 and
Huh7SF1 cells indicated that sorafenib resistance in
HCC cells was associated with an increase in the CSC
subpopulation and suggests the enrichment in CSCs as
the underlying cause of resistance to sorafenib treat-
ment in HCC.
Interestingly, these cells were refractory to sorafe-
nib-induced cell death and showed overactivation of
the Akt/mTOR pathway. Our finding that sorafenib
resistance was associated with Akt/mTOR upregula-
tion is in line with other previous studies (Jilkova
et al., 2018; Zhai et al., 2014; Zhu et al., 2017) and
reveals the importance of this pathway in drug
resistance.
The AMPK signalling pathway is a master regulator
of cellular energy homeostasis and metabolism whose
role in cancer is beginning to be revealed. There is
clinical evidence that the regular use of pharmacologi-
cal activators of AMPK to treat type 2 diabetes pro-
vides protection against the development of cancer
(Hardie, 2015). Metformin impairs oncogenic sig-
nalling pathways such as Akt/mTOR and receptor tyr-
osine kinase (Saini and Yang, 2018), providing a proof
of concept about the inhibitory role of activated
AMPK in cell proliferation. In this study, we explored
whether AMPK was involved in the drug resistance of
HCC. Our results showed that in sorafenib-resistant
HCC cells, there was a decrease in the phosphoryla-
tion, expression and activation of AMPK. A recent
study showed that sorafenib activated AMPK indi-
rectly by inhibiting mitochondrial function in HEK293
cells (Ross et al., 2017). The sorafenib doses used in
the previous study were higher than those used in the
current study (10-30 lM), and the treatment times were
shorter (1 h). Nevertheless, we observed a decrease in
AMPK phosphorylation in our model when cells
acquired resistance to sorafenib. Interestingly, AMPK
upregulation, either by pharmacological activation or
by transfection, was very successful not only in restor-
ing sorafenib sensitivity but also in reducing the
expression of most cancer stem markers analysed.
Conversely, AMPK inhibition or AMPK knockdown
induced sorafenib resistance in sensitive HCC cells.
These results indicate that chemoresistance to sorafe-
nib can be overcome by AMPK upregulation, suggest-
ing a promising clinical therapeutic strategy to fight
resistant HCC. This notion is in accordance with
recent findings demonstrating that resistance to sorafe-
nib may have a reversible phenotype (Kuczynski et al.,
2015).
Based on our aforementioned findings, we further
confirmed the relationship between AMPK and sorafe-
nib resistance in a mouse xenograft model. In vivo
studies demonstrated that HepG2SF1 cells possessed
higher tumourigenic potential and that tumours
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generated from these cells displayed stronger resistance
to sorafenib. In addition, HepG2SF1 tumours had
lower expression of AMPK and higher expression of
stem cell markers.
Although the role of AMPK in chemoresistance is
unknown, Zeng et al. (2018) recently showed that the
inhibition of LKB1 and consequently AMPK induced
docetaxel resistance in prostate cancer cells. Moreover,
additional findings support the concept that AMPK
activation could hinder the development of CSCs. For
instance, AMPK activation inhibits the sphere-forming
ability of the CSC subpopulation in breast, pancreatic
and ovarian cancer models (Saini and Yang, 2018). In
line with this notion, a recent study demonstrated that
CSCs from diabetic patients complicated with colorec-
tal carcinoma and treated with metformin showed
lower proliferation and higher rates of apoptosis than
those of patients not pretreated with metformin
(Zhang et al., 2013). In addition, metformin reduced
the proliferation, migration, invasion, sphere forma-
tion and stemness characteristics of osteosarcoma cells
in vitro (Chen et al., 2015c). In glioma cells, metformin
suppressed spheroid formation and size and inhibited
the expression of the glioma stemness-related marker
CD133 (Yuan et al., 2018). Although the role of
AMPK in the development of cancer stem cells has
not been established, there are recent reports demon-
strating that HepG2 cells transfected with CD90 have
higher expression of CD133 and lower levels of
AMPK phosphorylation (Chen et al., 2015b), which is
in line with our results. Likewise, recent data by Vaz-
quez-Martin et al. demonstrated that AMPK activa-
tion by metformin and A-769662 notably prevented
the transcriptional activation of Oct4 and impeded the
reprogramming of mouse embryonic fibroblasts (Vaz-
quez-Martin et al., 2012), which is in good agreement
with our results. The metformin-induced attenuation
of cancer stem cell features has also been reported by
two other groups. Bao et al. (2012) demonstrated that
metformin significantly decreased cell survival, clono-
genicity, sphere-forming capacity and the expression of
Oct4, Nanog and other CSC markers in pancreatic
cells. Furthermore, Jung et al. (2011) reported that
metformin decreased the size and number of mammo-
spheres and Oct4 expression in breast cancer MCF-7
cells. These data are in accordance with our results
and validate the notion that AMPK activation pre-
vents CSC function.
Recent data demonstrated that overexpression of the
Wnt/b-catenin signalling pathway induces rapid embry-
onic stem cell differentiation (Sun et al., 2017). How-
ever, the role of Wnt/b-catenin signalling in stem cell
reprogramming is controversial, as it seems that this
pathway is involved in both the maintenance of potency
and the induction of differentiation (Miki et al., 2011).
Our data indicate that b-catenin and cyclin D1 are
downregulated in stem-like cells and that AMPK over-
expression increases the levels of both proteins, suggest-
ing a role for this signalling pathway in the induction of
HCC stem cell differentiation. The transcriptional coac-
tivator PGC1a is a master regulator of mitochondrial
biogenesis and energy expenditure. PGC-1a directly
activates multiple transcription factors to regulate the
expression of a plethora of genes. Interestingly, AMPK
can regulate PGC-1a by increasing its expression and
phosphorylation. PGC-1a, in turn, has powerful tran-
scriptional activity by interacting with many different
transcription factors, such as PPARc. Our data reveal
that all these proteins are downregulated in sorafenib-
induced stem-like HCC cells, consistent with their
AMPK values and increase in AMPK-transfected cells.
In contrast, the hypoxia-inducible factor HIF-1a, which
has been revealed as a master regulator of the stemness
properties of cancer stem cells (Mimeault and Batra,
2013), is increased in HepG2SF1 and Huh7 cells com-
pared with their parental cells and decreased in AMPK-
transfected cells. These results are in good agreement
with previous results suggesting that the reduction in
AMPK activity is sufficient to increase HIF-1a protein
levels in cancer cells under normoxic conditions (Fau-
bert et al., 2013) and with the notion that HIF-1a regu-
lates the expression of stem cell markers such as Oct4,
Sox2 and Nanog in cancer cells (Lu et al., 2015; Zhang
et al., 2016). Likewise, in hepatospheres obtained from
hepatocellular carcinoma cell lines by incubation in a
defined medium, a marked increase in ABCB1A and
HIF-1a was observed and was associated with drug
resistance (Hashimoto et al., 2014), concordant with
our results.
5. Conclusions
Our data demonstrate that the downregulation of
AMPK by sorafenib treatment induces the enrichment
of HCC cells in CSCs, which is probably mediated by
HIF-1a. These CSCs have enhanced tumorigenicity,
clonogenic ability and differentiation capacity when
cultured in specific media as well as enhanced expres-
sion of the stem cell markers Oct4, Nanog,
ALDH1A1, ABCB1A and AFP. All these features can
be reversed by AMPK activation or overexpression. In
addition, AMPK upregulation restores sensibility to
sorafenib. Our results suggest a novel role for AMPK
in the chemotherapy resistance of hepatocellular carci-
noma and provide a new therapeutic strategy for
HCC.
17Molecular Oncology (2019) ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
A. Bort et al. AMPK impacts hepatocellular cancer stem cells
Acknowledgements
The authors would like to acknowledge D. Grahame
Hardie for providing the AMPK plasmids and Profes-
sor Lilian Puebla for critically reading the manuscript.
Authors acknowledge Wiley Editing Services for Eng-
lish language editing. This work was supported by the
Tatiana Perez de Guzman Foundation [grant number
Patrocinio 2013-01]. BSG is a fellowship from the
Spanish Education, Culture and Sports Ministry.
Author contributions
AB designed and performed the experiments and vali-
dated and performed the formal analysis of data. BS
designed and performed the experiments. PMG con-
tributed with methodology and critical reading of the
manuscript. DVC contributed with resources, method-
ology and critical reading of the manuscript. NRH
contributed with resources, the development of
methodology and revision of the manuscript and IDL
designed the study, wrote the paper, supervised the
research and acquired the financial support. All
authors reviewed the manuscript.
Conflicts of interest
The authors declare no conflict of interest.
References
Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH,
Banerjee S, Kong D, Li Y, Thakur S et al. (2012)
Metformin inhibits cell proliferation, migration and
invasion by attenuating CSC function mediated by
deregulating miRNAs in pancreatic cancer cells. Cancer
Prev Res (Phila) 5, 355–364.
Beal EW, Tumin D, Kabir A, Moris D, Zhang XF,
Chakedis J, Washburn K, Black S, Schmidt CM and
Pawlik TM (2017) Trends in the mortality of
hepatocellular carcinoma in the United States. J
Gastrointest Surg 21, 2033–2038.
Begicevic RR and Falasca M (2017) ABC transporters in
cancer stem cells: beyond chemoresistance. Int J Mol
Sci 18, 2362.
Bort A, Spinola E, Rodriguez-Henche N and
Diaz-Laviada I (2017) Capsaicin exerts synergistic
antitumor effect with sorafenib in hepatocellular
carcinoma cells through AMPK activation. Oncotarget
8, 87684–87698.
Castelli G, Pelosi E and Testa U (2017) Liver
cancer: molecular characterization, clonal
evolution and cancer stem cells. Cancers (Basel) 9,
127.
Charan J and Kantharia ND (2013) How to calculate
sample size in animal studies? J Pharmacol
Pharmacother 4, 303–306.
Chen WC, Chang YS, Hsu HP, Yen MC, Huang HL, Cho
CY, Wang CY, Weng TY, Lai PT, Chen CS et al.
(2015b) Therapeutics targeting CD90-integrin-AMPK-
CD133 signal axis in liver cancer. Oncotarget 6,
42923–42937.
Chen X, Hu C, Zhang W, Shen Y, Wang J, Hu F and Yu
P (2015c) Metformin inhibits the proliferation,
metastasis, and cancer stem-like sphere formation in
osteosarcoma MG63 cells in vitro. Tumour Biol 36,
9873–9883.
Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S,
Liang Y, Huang D, Liang X et al. (2015a) Potential
molecular, cellular and microenvironmental mechanism
of sorafenib resistance in hepatocellular carcinoma.
Cancer Lett 367, 1–11.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS,
Luo R, Feng J, Ye S, Yang TS et al. (2009) Efficacy
and safety of sorafenib in patients in the Asia-Pacific
region with advanced hepatocellular carcinoma: a
phase III randomised, double-blind, placebo-controlled
trial. Lancet Oncol 10, 25–34.
Colombo SL and Moncada S (2009) AMPKalpha1
regulates the antioxidant status of vascular endothelial
cells. Biochem J 421, 163–169.
Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M,
Dickinson R, Adler A, Gagne G, Iyengar R et al.
(2006) Identification and characterization of a small
molecule AMPK activator that treats key components
of type 2 diabetes and the metabolic syndrome. Cell
Metab 3, 403–416.
Dai XM, Yang SL, Zheng XM, Chen GG, Chen J and
Zhang T (2018) CD133 expression and
alpha-fetoprotein levels define novel prognostic
subtypes of HBV-associated hepatocellular carcinoma:
a long-term follow-up analysis. Oncol Lett 15, 2985–
2991.
Desai A, Yan Y and Gerson SL (2018) Concise reviews:
Cancer stem cell targeted therapies: toward clinical
success. Stem Cells Transl Med 66–67, 24–29.
Dong J, Zhai B, Sun W, Hu F, Cheng H and Xu J (2017)
Activation of phosphatidylinositol 3-kinase/AKT/snail
signaling pathway contributes to epithelial-
mesenchymal transition-induced multi-drug resistance
to sorafenib in hepatocellular carcinoma cells. PLoS
ONE 12, e0185088.
Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong
Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B et al.
(2013) AMPK is a negative regulator of the Warburg
effect and suppresses tumor growth in vivo. Cell Metab
17, 113–124.
Finley J (2017) Elimination of cancer stem cells and
reactivation of latent HIV-1 via AMPK activation:
18 Molecular Oncology (2019) ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
AMPK impacts hepatocellular cancer stem cells A. Bort et al.
common mechanism of action linking inhibition of
tumorigenesis and the potential eradication of HIV-1.
Med Hypotheses 104, 133–146.
Hardie DG (2015) Molecular pathways: Is AMPK a
friend or a foe in cancer? Clin Cancer Res 21,
3836–3840.
Hashimoto N, Tsunedomi R, Yoshimura K, Watanabe Y,
Hazama S and Oka M (2014) Cancer stem-like sphere
cells induced from de-differentiated hepatocellular
carcinoma-derived cell lines possess the resistance to
anti-cancer drugs. BMC Cancer 14, 722.
Heddleston JM, Li Z, McLendon RE, Hjelmeland AB and
Rich JN (2009) The hypoxic microenvironment
maintains glioblastoma stem cells and promotes
reprogramming towards a cancer stem cell phenotype.
Cell Cycle 8, 3274–3284.
Iv Santaliz-Ruiz LE, Xie X, Old M, Teknos TN and Pan Q
(2014) Emerging role of nanog in tumorigenesis and
cancer stem cells. Int J Cancer 135, 2741–2748.
Jang JW, Song Y, Kim SH, Kim JS, Kim KM, Choi EK,
Kim J and Seo HR (2017b) CD133 confers cancer
stem-like cell properties by stabilizing EGFR-AKT
signaling in hepatocellular carcinoma. Cancer Lett 389,
1–10.
Jang JW, Song Y, Kim SH, Kim J and Seo HR (2017a)
Potential mechanisms of CD133 in cancer stem cells.
Life Sci 184, 25–29.
Jiao X, Cai J, Yu X and Ding X (2017) Paracrine
activation of the Wnt/beta-catenin pathway by bone
marrow stem cell attenuates cisplatin-induced kidney
injury. Cell Physiol Biochem 44, 1980–1994.
Jilkova ZM, Kuyucu AZ, Kurma K, Ahmad Pour ST,
Roth GS, Abbadessa G, Yu Y, Schwartz B, Sturm N,
Marche PN et al. (2018) Combination of AKT
inhibitor ARQ 092 and sorafenib potentiates inhibition
of tumor progression in cirrhotic rat model of
hepatocellular carcinoma. Oncotarget 9, 11145–11158.
Jung JW, Park SB, Lee SJ, Seo MS, Trosko JE and Kang
KS (2011) Metformin represses self-renewal of the
human breast carcinoma stem cells via inhibition of
estrogen receptor-mediated OCT4 expression. PLoS
ONE 6, e28068.
Kuczynski EA, Lee CR, Man S, Chen E and Kerbel RS
(2015) Effects of sorafenib dose on acquired reversible
resistance and toxicity in hepatocellular carcinoma.
Cancer Res 75, 2510–2519.
Kudo M (2017) Systemic therapy for hepatocellular
carcinoma: 2017 update. Oncology 93(Suppl 1), 135–146.
Kudo M (2018) Lenvatinib may drastically change the
treatment landscape of hepatocellular carcinoma. Liver
Cancer 7, 1–19.
Le Grazie M, Biagini MR, Tarocchi M, Polvani S and
Galli A (2017) Chemotherapy for hepatocellular
carcinoma: the present and the future. World J Hepatol
9, 907–920.
Lee S, Wottrich S and Bonavida B (2017) Crosstalks
between Raf-kinase inhibitor protein and cancer stem
cell transcription factors (Oct4, KLF4, Sox2, Nanog).
Tumour Biol 39, 1–17.
Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos
A, Kabir NN, Sun J, Vallon-Christersson J,
Haraldsson K, Hemann MT et al. (2016) Aberrant
activation of the PI3K/mTOR pathway promotes
resistance to sorafenib in AML. Oncogene 35, 5119–
5131.
Ling S, Tian Y, Zhang H, Jia K, Feng T, Sun D, Gao Z,
Xu F, Hou Z, Li Y et al. (2014) Metformin reverses
multidrug resistance in human hepatocellular
carcinoma Bel7402/5fluorouracil cells. Mol Med Rep
10, 2891–2897.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E,
Blanc JF, de Oliveira AC, Santoro A, Raoul JL,
Forner A et al. (2008) Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med 359, 378–390.
Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen I,
Bullen JW and Semenza GL (2015) Chemotherapy
triggers HIF-1-dependent glutathione synthesis and
copper chelation that induces the breast cancer stem
cell phenotype. Proc Natl Acad Sci USA 112, E4600–
E4609.
Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ
and Guan XY (2008a) Aldehyde dehydrogenase
discriminates the CD133 liver cancer stem cell
populations. Mol Cancer Res 6, 1146–1153.
Ma S, Lee TK, Zheng BJ, Chan KW and Guan XY
(2008b) CD133 + HCC cancer stem cells
confer chemoresistance by preferential expression of
the Akt/PKB survival pathway. Oncogene 27, 1749–
1758.
Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T,
Nesland JM and Suo Z (2011) Prostate cancer cell lines
under hypoxia exhibit greater stem-like properties.
PLoS ONE 6, e29170.
Miki T, Yasuda SY and Kahn M (2011) Wnt/beta-catenin
signaling in embryonic stem cell self-renewal and
somatic cell reprogramming. Stem Cell Rev 7, 836–846.
Mimeault M and Batra SK (2013) Hypoxia-inducing
factors as master regulators of stemness properties and
altered metabolism of cancer- and metastasis-initiating
cells. J Cell Mol Med 17, 30–54.
Paiva-Oliveira DI, Martins-Neves SR, Abrunhosa AJ,
Fontes-Ribeiro C and Gomes CMF (2018) Therapeutic
potential of the metabolic modulator Metformin on
osteosarcoma cancer stem-like cells. Cancer Chemother
Pharmacol 81, 49–63.
Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS,
Lee YK and Kwon HY (2018) Cancer stem cells
(CSCs) in drug resistance and their therapeutic
implications in cancer treatment. Stem Cells Int 2018,
5416923.
19Molecular Oncology (2019) ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
A. Bort et al. AMPK impacts hepatocellular cancer stem cells
Rajendran V and Jain MV (2018) In vitro tumorigenic
assay: colony forming assay for cancer stem cells.
Methods Mol Biol 1692, 89–95.
Ross FA, Hawley SA, Auciello FR, Gowans GJ, Atrih A,
Lamont DJ and Hardie DG (2017) Mechanisms of
paradoxical activation of AMPK by the kinase
inhibitors SU6656 and Sorafenib. Cell Chem Biol 24
(813–824), e814.
Saini N and Yang X (2018) Metformin as an anti-cancer
agent: actions and mechanisms targeting cancer stem
cells. Acta Biochim Biophys Sin (Shanghai) 50,
133–143.
van Schaijik B, Davis PF, Wickremesekera AC, Tan ST
and Itinteang T (2018) Subcellular localisation of the
stem cell markers OCT4, SOX2, NANOG, KLF4 and
c-MYC in cancer: a review. J Clin Pathol 71, 88–91.
Seymour T, Twigger AJ and Kakulas F (2015)
Pluripotency genes and their functions in the normal
and aberrant breast and brain. Int J Mol Sci 16,
27288–27301.
Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, Xu Y, Ma
Q, Yang Z, Zhang Q et al. (2012) Nanog regulates
self-renewal of cancer stem cells through the insulin-
like growth factor pathway in human hepatocellular
carcinoma. Hepatology 56, 1004–1014.
Siegel RL, Miller KD and Jemal A (2018) Cancer statistics,
2018. CA Cancer J Clin 68, 7–30.
Spallanzani A, Orsi G, Andrikou K, Gelsomino F, Rimini
M, Riggi L and Cascinu S (2018) Lenvatinib as a
therapy for unresectable hepatocellular carcinoma.
Expert Rev Anticancer Ther 18, 1069–1076.
Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T
and Moriwaki H (2006) Characterization of
CD133 + hepatocellular carcinoma cells as cancer
stem/progenitor cells. Biochem Biophys Res Commun
351, 820–824.
Sun H, Wang X, Liu K, Guo M, Zhang Y, Ying QL and
Ye S (2017) Beta-catenin coordinates with Jup and the
TCF1/GATA6 axis to regulate human embryonic stem
cell fate. Dev Biol 431, 272–281.
Tovoli F, Negrini G, Benevento F, Faggiano C, Goio E
and Granito A (2018) Systemic treatments for
hepatocellular carcinoma: challenges and future
perspectives. Hepat Oncol 5, HEP01.
Valkenburg KC, Graveel CR, Zylstra-Diegel CR, Zhong Z
and Williams BO (2011) Wnt/beta-catenin signaling in
normal and cancer stem cells. Cancers (Basel) 3,
2050–2079.
Vara D, Salazar M, Olea-Herrero N, Guzman M, Velasco
G and Diaz-Laviada I (2011) Anti-tumoral action of
cannabinoids on hepatocellular carcinoma: role of
AMPK-dependent activation of autophagy. Cell Death
Differ 18, 1099–1111.
Vazquez-Martin A, Vellon L, Quiros PM, Cufi S, Ruiz
de Galarreta E, Oliveras-Ferraros C, Martin AG,
Martin-Castillo B, Lopez-Otin C and Menendez JA
(2012) Activation of AMP-activated protein kinase
(AMPK) provides a metabolic barrier to
reprogramming somatic cells into stem cells. Cell
Cycle 11, 974–989.
Wanet A, Caruso M, Domelevo Entfellner JB, Najar M,
Fattaccioli A, Demazy C, Evraerts J, El-Kehdy H,
Pourcher G, Sokal E et al. (2017) The transcription
factor 7-like 2-peroxisome proliferator-activated
receptor gamma coactivator-1 alpha axis connects
mitochondrial biogenesis and metabolic shift with stem
cell commitment to hepatic differentiation. Stem Cells
35, 2184–2197.
Wu CH, Wu X and Zhang HW (2016) Inhibition of
acquired-resistance hepatocellular carcinoma cell
growth by combining sorafenib with phosphoinositide
3-kinase and rat sarcoma inhibitor. J Surg Res 206,
371–379.
Yi H, Ye X, Long B, Ye T, Zhang L, Yan F, Yang Y
and Li L (2017) Inhibition of the AKT/mTOR
pathway augments the anticancer effects of sorafenib
in thyroid cancer. Cancer Biother Radiopharm 32,
176–183.
You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui
Y, Fang F, Zhang W et al. (2016) Metformin sensitizes
sorafenib to inhibit postoperative recurrence and
metastasis of hepatocellular carcinoma in orthotopic
mouse models. J Hematol Oncol 9, 20.
Yuan X, Wei W, Bao Q, Chen H, Jin P and Jiang W
(2018) Metformin inhibits glioma cells stemness and
epithelial-mesenchymal transition via regulating YAP
activity. Biomed Pharmacother 102, 263–270.
Zeng J, Liu W, Fan YZ, He DL and Li L (2018) PrLZ
increases prostate cancer docetaxel resistance by
inhibiting LKB1/AMPK-mediated autophagy.
Theranostics 8, 109–123.
Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B, Pan S, Dong
X, Tan G, Wei Z et al. (2014) Inhibition of Akt
reverses the acquired resistance to sorafenib by
switching protective autophagy to autophagic cell
death in hepatocellular carcinoma. Mol Cancer Ther
13, 1589–1598.
Zhang Y, Guan M, Zheng Z, Zhang Q, Gao F and Xue Y
(2013) Effects of metformin on
CD133 + colorectal cancer cells in diabetic patients.
PLoS ONE 8, e81264.
Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I,
He X and Semenza GL (2016) Hypoxia induces the
breast cancer stem cell phenotype by HIF-dependent
and ALKBH5-mediated m(6)A-demethylation of
NANOG mRNA. Proc Natl Acad Sci USA 113,
E2047–E2056.
Zheng YW, Nie YZ and Taniguchi H (2013) Cellular
reprogramming and hepatocellular carcinoma
development. World J Gastroenterol 19, 8850–8860.
20 Molecular Oncology (2019) ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
AMPK impacts hepatocellular cancer stem cells A. Bort et al.
Zhu YJ, Zheng B, Wang HY and Chen L (2017) New
knowledge of the mechanisms of sorafenib resistance in
liver cancer. Acta Pharmacol Sin 38, 614–622.
Supporting information
Additional supporting information may be found
online in the Supporting Information section at the end
of the article.
Fig. S1. Expression of stem cell markers in hepatocel-
lular carcinoma cells treated with sorafenib for 6 and
12 months. HepG2 and Huh7 cells were cultured con-
tinuously for 12 months with a step-wise increase in
sorafenib concentrations (0.75–8 lM). (A) The levels of
AFP, CD133 and ALDH1A1 were determined by
western blot at 6 (cells grown in 4 lM sorafenib) and
12 (cells grown in 8 lM sorafenib) months. b-Actin is
shown as a loading control. (B) Flow cytometry his-
tograms of CD133 in HepG2 and Huh7 parental cells
and in cells treated with sorafenib for 12 months
(HepG2SF1 and Huh7SF1). Images are representative
of two independent experiments.
Fig. S2. Flow cytometry histograms of CD133 in
HepG2, Huh7, HepG2SF1 and Huh7SF1 cells trans-
fected with an siRNA selective for AMPK or with a
plasmid containing AMPK a1b1c1. Images are repre-
sentative of two independent experiments.
Fig. S3. Effect of AMPK inhibition on sorafenib sensi-
tivity in stem-like HCC cells. (A) Effect of the AMPK
inhibitor dorsomorphin (Dorso) on HepG2SF1 and
Huh7SF1 cell viability inhibition induced by sorafenib.
Cells were treated with or without 5 lM dorsomorphin
and sorafenib at the indicated concentrations for 24 h.
(B) Effect of AMPK knockdown with an siRNA on
HepG2SF1 and Huh7SF1 cell viability inhibition
induced by sorafenib. Cell viability was determined by
the MTT assay and is expressed as the percentage of
the control (DMSO treatment). (C) The levels of phos-
phorylated and total forms of AMPK and ACC in
HCC cells were determined by western blot. b-Tubulin
(bTub) is shown as a loading control. A representative
image of four different experiments is shown. Densito-
metric values (mean  SD, n = 3) relative to controls
are shown below. *P < 0.005 significant difference
between resistant and control cells and #P < 0.005
between treated and nontreated cells by two-way
ANOVA and Tukey’s multiple comparisons test.
Experiments were run in triplicate and carried out at
least two times on separate occasions.
Fig. S4. Effect of AMPK transfection or activation on
sorafenib sensitivity in HepG2 and Huh7 cells. (A)
The levels of pAMPK, AMPK, pACC and ACC in
HepG2 and Huh7 cells transfected with AMPK
a1b1c1 were determined by western blot. Densitomet-
ric values (mean  SD, n = 4) relative to controls are
shown on the right. (B) Effect of the transient expres-
sion of AMPK1b1c1 on cell viability in HepG2 and
Huh7 cells treated with increasing concentrations of
sorafenib. Cells were treated with sorafenib at the indi-
cated concentrations for 24 h. Cell viability was deter-
mined by the MTT assay and is expressed as the
percentage of the control (DMSO treatment). (C)
Effect of the AMPK activator A-769662 and capsaicin
on HepG2SF1 and Huh7SF1 cell viability following
treatment with increasing concentrations of sorafenib.
Cells were treated as described above. Experiments
were run in triplicate and carried out at least three
times on separate occasions. Data are the mean  SD,
n = 3.*P < 0.005 significant difference between stem-
like and parental cells by two-way ANOVA and
Tukey’s multiple comparisons test, #P < 0.005 signifi-
cant difference between AMPK-transfected and non-
transfected cells (panel A and B) or between control
and treated cells (panels C).
Fig. S5. Putative mechanism involved in stemness in
cells treated long term with sorafenib. In cells sensitive
to sorafenib, high levels of AMPK inhibit HIF-1a
while enhancing PGC1a, PPARc and b-catenin. In
sorafenib-resistant cells, long-term treatment with sora-
fenib induces a depletion of AMPK, releasing HIF-1a
inhibition, which regulates the transcription of stem-
related genes, such as Nanog and Oct4, promoting
stemness.
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